Labcorp® Plasma Detect™ : A ctDNA assay for tumor-informed detection of
An advanced approach integrating WGS and proprietary machine learning to assess MRD
Building on a comprehensive portfolio of tissue, liquid biopsy and immune profiling solutions for solid tumors, Labcorp Plasma Detect provides precision monitoring for accelerated clinical trial enrichment strategies and enhanced therapeutic response assessment.
Assess the effectiveness of treatment and identify disease recurrence with an innovative tumor-informed ctDNA molecular residual disease (MRD) assay. This advanced approach integrates whole genome sequencing (WGS) and a proprietary machine learning analysis to identify a high-confidence, patient-specific mutation signature and track it over time—without the need for bespoke panel development.
...
More Info Less Info